Paper41001799
In silico Study of Novel Tryptanthrin-Based Topoisomerase Inhibitors.
Kumawat MK and 1 other. Med Chem, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. In silico Study of Novel Tryptanthrin-Based Topoisomerase Inhibitors. Papers, record 41001799. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41001799
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Quinazolines | Major topic |
| Antineoplastic Agents | Major topic |
| Topoisomerase Inhibitors | Major topic |
| Molecular Docking Simulation | |
| Humans | |
| Structure-Activity Relationship | |
| Computer Simulation | |
| Molecular Structure | |
| Ligands |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28720329 | Recent synthetic and medicinal perspectives of tryptanthrin. | Bioorg Med Chem | 2017 | https://conductscience.org/library/papers/28720329 | PubMed |
| 2 | 32025510 | 2-Phenylethanol and 2-phenylethylacetate production by nonconventional yeasts using tequila vinasses as a substrate. | Biotechnol Rep (Amst) | 2020 | https://conductscience.org/library/papers/32025510 | PubMed |
| 3 | 26394469 | [Study of Antioxidant and Membranotropic Activities of Quinazoline Alkaloid Tryptanthrin Using Different Model Systems]. | Biofizika | 2015 | https://conductscience.org/library/papers/26394469 | PubMed |
| 4 | 32357298 | Discovery of Tryptanthrins as Novel Antiviral and Anti-Phytopathogenic-Fungus Agents. | J Agric Food Chem | 2020 | https://conductscience.org/library/papers/32357298 | PubMed |
| 5 | 32792961 | Therapeutic Effects of Tryptanthrin and Tryptanthrin-6-Oxime in Models of Rheumatoid Arthritis. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32792961 | PubMed |
| 6 | 23543631 | Progress in the studies on tryptanthrin, an alkaloid of history. | Arch Pharm Res | 2013 | https://conductscience.org/library/papers/23543631 | PubMed |
| 7 | 23360475 | Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents. | J Nat Prod | 2013 | https://conductscience.org/library/papers/23360475 | PubMed |
| 8 | 29485730 | Biologically active quinoline and quinazoline alkaloids part II. | Med Res Rev | 2018 | https://conductscience.org/library/papers/29485730 | PubMed |
| 9 | 32024909 | Tryptanthrin promotes keratinocyte and fibroblast responses in vitro after infection with Trichophyton benhamiae DSM6916. | Sci Rep | 2020 | https://conductscience.org/library/papers/32024909 | PubMed |
| 10 | 32455240 | Arene-Ruthenium(II) Complexes Containing 11H-Indeno[1,2-b]quinoxalin-11-one Derivatives and Tryptanthrin-6-oxime: Synthesis, Characterization, Cytotoxicity, and Catalytic Transfer Hydrogenation of Aryl Ketones. | ACS Omega | 2020 | https://conductscience.org/library/papers/32455240 | PubMed |
| 11 | 34735707 | Tryptanthrin derivatives as efficient singlet oxygen sensitizers. | Photochem Photobiol Sci | 2022 | https://conductscience.org/library/papers/34735707 | PubMed |
| 12 | 20139909 | Cytotoxicity and reversal of multidrug resistance by tryptanthrin-derived indoloquinazolines. | Acta Pharmacol Sin | 2010 | https://conductscience.org/library/papers/20139909 | PubMed |
| 13 | 36674964 | Discovery of Tryptanthrin and Its Derivatives and Its Activities against NSCLC In Vitro via Both Apoptosis and Autophagy Pathways. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36674964 | PubMed |
| 14 | 32945360 | Design, synthesis and biomedical evaluation of mostotrin, a new water soluble tryptanthrin derivative. | Int J Mol Med | 2020 | https://conductscience.org/library/papers/32945360 | PubMed |
| 15 | 37895927 | Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37895927 | PubMed |
| 16 | 39034729 | A Novel Tryptanthrin Derivative D6 Induces Apoptosis and DNA Damage in Non-small-cell Lung Cancer Cells Through Regulating the EGFR Pathway. | Anticancer Agents Med Chem | 2024 | https://conductscience.org/library/papers/39034729 | PubMed |
| 17 | 38665827 | Recent advances of tryptanthrin and its derivatives as potential anticancer agents. | RSC Med Chem | 2024 | https://conductscience.org/library/papers/38665827 | PubMed |
| 18 | 37375361 | Novel Tryptanthrin Derivatives with Selectivity as c-Jun N-Terminal Kinase (JNK) 3 Inhibitors. | Molecules | 2023 | https://conductscience.org/library/papers/37375361 | PubMed |
| 19 | 11422788 | Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U-937 and HL-60) by tryptanthrin, an active ingredient of Polygonum tinctorium Lour. | Pathol Int | 2001 | https://conductscience.org/library/papers/11422788 | PubMed |
| 20 | 19887046 | Modulatory effects and action mechanisms of tryptanthrin on murine myeloid leukemia cells. | Cell Mol Immunol | 2009 | https://conductscience.org/library/papers/19887046 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41001799
GET https://conductscience.org/api/papers/v1/41001799/references?page=2